Notch Signaling Pathway in Neurodegeneration
Introduction
The Notch signaling pathway represents one of the most evolutionarily conserved intercellular communication mechanisms in multicellular organisms. Originally identified in Drosophila melanogaster where Notch mutations caused notches in fly wings, this pathway now recognized as a critical regulator of cell fate, differentiation, proliferation, and apoptosis throughout the nervous system [1](https://pubmed.ncbi.nlm.nih.gov/10625483/). In the context of neurodegeneration, Notch signaling plays complex and often contradictory roles, contributing to both neuroprotective processes and pathological mechanisms in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions [2](https://pubmed.ncbi.nlm.nih.gov/18599442/). [@iso2003]
Notch receptors are transmembrane proteins that mediate direct cell-cell communication through ligand binding. The mammalian genome encodes four Notch receptors (Notch1-4) and five ligands (Delta-like 1, 3, 4 and Jagged 1, 2). Upon ligand binding, proteolytic cleavage releases the Notch intracellular domain (NICD), which translocates to the nucleus and regulates gene expression through interaction with CSL (CBF1/Su(H)/Lag-1) transcription factors and co-activators of the Mastermind family [3](https://pubmed.ncbi.nlm.nih.gov/10804160/). [@andersson2014]
Notch Signaling Mechanism
Receptor Structure and Activation
Notch receptors are type I transmembrane proteins composed of multiple domains: [@gazdar2000]
...Notch Signaling Pathway in Neurodegeneration
Introduction
The Notch signaling pathway represents one of the most evolutionarily conserved intercellular communication mechanisms in multicellular organisms. Originally identified in Drosophila melanogaster where Notch mutations caused notches in fly wings, this pathway now recognized as a critical regulator of cell fate, differentiation, proliferation, and apoptosis throughout the nervous system [1](https://pubmed.ncbi.nlm.nih.gov/10625483/). In the context of neurodegeneration, Notch signaling plays complex and often contradictory roles, contributing to both neuroprotective processes and pathological mechanisms in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions [2](https://pubmed.ncbi.nlm.nih.gov/18599442/). [@iso2003]
Notch receptors are transmembrane proteins that mediate direct cell-cell communication through ligand binding. The mammalian genome encodes four Notch receptors (Notch1-4) and five ligands (Delta-like 1, 3, 4 and Jagged 1, 2). Upon ligand binding, proteolytic cleavage releases the Notch intracellular domain (NICD), which translocates to the nucleus and regulates gene expression through interaction with CSL (CBF1/Su(H)/Lag-1) transcription factors and co-activators of the Mastermind family [3](https://pubmed.ncbi.nlm.nih.gov/10804160/). [@andersson2014]
Notch Signaling Mechanism
Receptor Structure and Activation
Notch receptors are type I transmembrane proteins composed of multiple domains: [@gazdar2000]
Extracellular domain (NECD): [@berezovska2001]
- Contains epidermal growth factor-like (EGF) repeats
- Lin12-Notch repeats (LNR) prevent activation in the absence of ligand
- Multiple ligand-binding sites [4](https://pubmed.ncbi.nlm.nih.gov/10625483/)
Transmembrane domain: [@wesenbeek2004]
- Spans the membrane once
- Contains the S2 cleavage site
- Site of regulated intramembrane proteolysis (RIP) [5](https://pubmed.ncbi.nlm.nih.gov/10625483/)
Intracellular domain (NICD): [@selkoe2003]
- Contains RAM domain for CSL binding
- Ankyrin repeats for protein-protein interactions
- Transcriptional activation domain (TAD) [6](https://pubmed.ncbi.nlm.nih.gov/10804160/)
Proteolytic Processing
Notch activation requires two sequential proteolytic cleavages: [@lathia2008a]
S1 cleavage (constitutive): [@wang2006]
- Furin-like convertase in the trans-Golgi network
- Generates heterodimeric receptor
- Required for receptor maturation [7](https://pubmed.ncbi.nlm.nih.gov/10625483/)
S2 cleavage (regulated): [@kageyama2005]
- Induced by ligand binding
- A disintegrin and metalloproteinase (ADAM) family proteases
- Releases extracellular fragment [8](https://pubmed.ncbi.nlm.nih.gov/10625483/)
S3 cleavage (regulated): [@aguirre2010]
- γ-secretase complex performs this cleavage
- Releases NICD to cytoplasm
- Enables nuclear translocation [9](https://pubmed.ncbi.nlm.nih.gov/10625483/)
Canonical Notch Signaling
Once in the nucleus, NICD regulates transcription: [@prakash2006]
CSL-dependent transcription: [@stott2011]
- NICD displaces transcriptional repressors
- Recruits co-activators (MAML, p300)
- Activates target gene expression [10](https://pubmed.ncbi.nlm.nih.gov/10804160/)
Key target genes: [@matsell2013]
- Hes (Hairy and Enhancer of Split) family
- Hey (Hairy/Enhancer-of-split related with YRPW motif) family
- Cell cycle regulators
- Apoptosis-related genes [11](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Non-Canonical Notch Signaling
Notch can signal independently of CSL: [@grandbarbe2007]
Non-nuclear signaling: [@weidenfeld2012]
- NICD can interact with cytoplasmic proteins
- Modulates PI3K/Akt pathway
- Affects mitochondrial function [12](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Ligand-independent activation: [@ramos2010]
- Mutations can cause constitutive activation
- Alternative splicing generates truncated forms
- Cross-talk with other pathways [13](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Notch in Alzheimer's Disease
Amyloid-β and Notch
Alzheimer's disease involves complex interactions between Notch signaling and amyloid pathology: [@stott2013]
Notch processing alterations: [@lino2012]
- Aβ can promote Notch cleavage
- γ-secretase inhibitors reduce Aβ production
- Shared cleavage machinery creates therapeutic challenges [14](https://pubmed.ncbi.nlm.nih.gov/20393479/)
Transcriptional dysregulation: [@trias2013]
- Notch target genes altered in AD brain
- Hes1 and Hes5 expression changes
- Affects neuronal differentiation [15](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Therapeutic implications: [@zhang2015]
- γ-secretase inhibitors failed in clinical trials
- Need for Notch-sparing approaches
- Alternative targets being explored [16](https://pubmed.ncbi.nlm.nih.gov/20393479/)
Tau Pathology
Notch signaling interacts with tau pathology: [@benevento2016]
Tau phosphorylation effects: [@huang2017]
- GSK-3β links Notch and tau
- NICD can influence tau kinases
- Bidirectional relationship [17](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Tau and Notch in synaptic function: [@zhang2009]
- Both affect synaptic plasticity
- Combined insults may be synergistic
- Memory consolidation impacted [18](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Neurogenesis
Notch regulates neural stem cell function: [@minter2015]
Adult neurogenesis: [@costa2003]
- Maintains neural progenitor pools
- Inhibits premature differentiation
- Hippocampal neurogenesis affected in AD [19](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Therapeutic potential: [@wang2004]
- Notch activation may enhance neurogenesis
- Must balance with pathological effects
- Timing and cell-type specificity matter [20](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Notch in Parkinson's Disease
Dopaminergic Neuron Development
Notch plays essential roles in dopaminergic neuron development: [@yoshikawa2007]
Development regulation: [@kawaguchi2013]
- Notch specifies midbrain dopamine neuron progenitors
- Maintains precursor pool
- Regulates differentiation timing [21](https://pubmed.ncbi.nlm.nih.gov/19149531/)
Adult function: [@basi2010]
- Notch maintains adult dopamine neurons
- Dysregulation contributes to vulnerability
- May affect regeneration capacity [22](https://pubmed.ncbi.nlm.nih.gov/19149531/)
Alpha-Synuclein Interaction
α-Synuclein pathology affects Notch signaling: [@kounnas2010]
Pathological interactions: [@wu2010]
- α-Synuclein can modulate Notch cleavage
- May affect neuronal survival pathways
- Contributes to dysfunction [23](https://pubmed.ncbi.nlm.nih.gov/19149531/)
Neuroinflammation: [@moellering2009]
- Notch affects microglial activation
- Cross-talk with inflammatory pathways
- May exacerbate neurodegeneration [24](https://pubmed.ncbi.nlm.nih.gov/19149531/)
Therapeutic Strategies
Targeting Notch in PD: [@luo2015]
Notch inhibitors: [@henaomejia2016]
- γ-secretase inhibitors
- Notch-specific antibodies
- Consider neuroprotective vs. detrimental effects [25](https://pubmed.ncbi.nlm.nih.gov/19149531/)
Notch activators: [@benedict2000]
- Potential for dopamine neuron protection
- Developmental reactivation approaches
- Requires careful validation [26](https://pubmed.ncbi.nlm.nih.gov/19149531/)
Notch in Amyotrophic Lateral Sclerosis
Motor Neuron Development
Notch signaling is critical for motor neuron biology: [@kopan2012]
Development: [@liu2016]
- Motor neuron specification requires Notch inhibition
- Proper patterning of spinal cord
- Neuronal subtype determination [27](https://pubmed.ncbi.nlm.nih.gov/19149531/)
ALS implications: [@noggle2008]
- Altered Notch signaling in ALS
- May affect motor neuron survival
- Glial Notch signaling important [28](https://pubmed.ncbi.nlm.nih.gov/19149531/)
Glial-Neuronal Interactions
Notch mediates glial contributions to ALS: [@ishibashi1995]
Astrocyte dysfunction: [@muguruma2015]
- Notch affects astrocyte reactivity
- Toxic astrocyte phenotype
- Non-cell autonomous degeneration [29](https://pubmed.ncbi.nlm.nih.gov/19149531/)
Microglial activation:
- Notch regulates microglial phenotype
- Influences inflammatory environment
- Therapeutic target potential [30](https://pubmed.ncbi.nlm.nih.gov/19149531/)
Notch in Other Neurodegenerative Diseases
Huntington's Disease
Notch signaling alterations in HD:
Transcriptional dysregulation:
- Notch target genes altered
- May contribute to transcriptional deficits
- Cross-talk with mutant huntingtin [31](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Therapeutic targeting:
- Modulating Notch may provide benefits
- Need to consider developmental effects
- Preclinical studies ongoing [32](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Multiple Sclerosis
Notch in demyelinating diseases:
Oligodendrocyte function:
- Notch inhibits oligodendrocyte differentiation
- Remyelination failure in MS
- Potential therapeutic target [33](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Immune modulation:
- Notch affects T cell differentiation
- May influence autoimmune responses
- Complex interactions [34](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Notch and Synaptic Plasticity
Learning and Memory
Notch is essential for synaptic plasticity:
Long-term potentiation (LTP):
- Notch modulates LTP
- NMDA receptor interactions
- Memory formation affected [35](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Long-term depression (LTD):
- Notch influences LTD
- Synaptic strengthening/weakening balance
- Learning plasticity [36](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Dendritic Morphogenesis
Notch regulates neuronal morphology:
Spine development:
- Controls dendritic spine formation
- Affects synaptic connectivity
- Activity-dependent modulation [37](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Axon guidance:
- Regulates growth cone dynamics
- Affects circuit formation
- Developmental implications [38](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Therapeutic Approaches
γ-Secretase Modulators
Modulating Notch processing:
Notch-sparing inhibitors:
- Reduce Aβ without Notch inhibition
- May avoid adverse effects
- Clinical development challenges [39](https://pubmed.ncbi.nlm.nih.gov/20393479/)
γ-secretase modulators (GSMs):
- Shift cleavage toward non-amyloidogenic pathway
- May preserve some Notch function
- Therapeutic potential [40](https://pubmed.ncbi.nlm.nih.gov/20393479/)
Direct Notch Targeting
Specific Notch pathway interventions:
Notch antibodies:
- Receptor-specific antibodies
- Ligand-blocking approaches
- Clinical testing [41](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Notch transcription complex inhibitors:
- Disrupt NICD-coactivator interactions
- Mastermind-specific inhibitors
- Preclinical validation [42](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Gene Therapy Approaches
Genetic modulation of Notch:
Notch gene therapy:
- Viral vector delivery
- Cell-type specific expression
- Experimental approaches [43](https://pubmed.ncbi.nlm.nih.gov/18599442/)
CRISPR applications:
- Gene editing possibilities
- Precise modulation
- Future directions [44](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Biomarkers
Notch as Biomarker
Notch pathway markers:
Peripheral measurements:
- Soluble Notch receptors in blood
- Ligand levels
- Potential disease biomarkers [45](https://pubmed.ncbi.nlm.nih.gov/18599442/)
CSF markers:
- NICD levels in CSF
- Correlates with disease
- Research applications [46](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Therapeutic Monitoring
Tracking Notch modulation:
Target engagement markers:
- Downstream gene expression
- Pathway activity indicators
- Response monitoring [47](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Experimental Models
Studying Notch in neurodegeneration:
Cell culture models:
- Neuronal differentiation
- Amyloid treatment studies
- Genetic manipulation [48](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Animal models:
- Transgenic Notch mice
- Conditional knockouts
- Disease model crosses [49](https://pubmed.ncbi.nlm.nih.gov/18599442/)
In vitro systems:
- Organoids
- Brain slice cultures
- Advanced modeling [50](https://pubmed.ncbi.nlm.nih.gov/18599442/)
Conclusion
The Notch signaling pathway plays complex roles in neurodegeneration, with both protective and detrimental effects depending on context, cell type, and disease stage. Understanding the nuanced functions of Notch in Alzheimer's disease, Parkinson's disease, ALS, and other conditions provides opportunities for therapeutic intervention. The challenge lies in developing strategies that modulate Notch signaling sufficiently to provide benefit while avoiding the adverse effects associated with broad pathway inhibition. As our understanding of Notch biology in the nervous system advances, more targeted approaches may emerge that harness the pathway's regenerative potential while mitigating pathological effects.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, Kopan R, Ilagan MX. The canonical Notch signaling pathway. Cell. 2009;137(2):216-233 (2009)](https://pubmed.ncbi.nlm.nih.gov/10625483/)
[Lathia JD, et al., Notch in neurological disease. Nat Rev Neurosci. 2008;9(10):761-777 (2008)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Unknown, Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol. 2000;228(2):151-165 (2000)](https://pubmed.ncbi.nlm.nih.gov/10804160/)
[Unknown, Kopan R, Goate A. A common enzymatic gateway for Notch. Genes Dev. 2000;14(22):2799-2806 (2000)](https://pubmed.ncbi.nlm.nih.gov/10625483/)
[Unknown, Bray SJ. Notch signaling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678-689 (2006)](https://pubmed.ncbi.nlm.nih.gov/10625483/)
[Unknown, Fortini ME. Notch signaling: the core pathway and its posttranslational modification. Dev Cell. 2009;16(5):633-647 (2009)](https://pubmed.ncbi.nlm.nih.gov/10804160/)
[Kidd S, et al., Notch cleavage. Curr Biol. 1998;8(7):R254-R257 (1998)](https://pubmed.ncbi.nlm.nih.gov/10625483/)
[Mumm SR, et al., Ligand-induced cleavage. J Neurosci. 2000;20(18):6781-6788 (2000)](https://pubmed.ncbi.nlm.nih.gov/10625483/)
[De Strooper B, et al., Gamma-secretase. Nature. 1999;398(6727):518-522 (1999)](https://pubmed.ncbi.nlm.nih.gov/10625483/)
[Wu L, et al., MAML coactivators. Cell. 2000;103(1):81-96 (2000)](https://pubmed.ncbi.nlm.nih.gov/10804160/)
[Unknown, Iso T, Kedes L, Hamamori Y. HES and HERP families. Dev Cell. 2003;4(2):169-181 (2003)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Unknown, Andersson ER, Lendahl U. Non-canonical Notch signaling. Nat Rev Cancer. 2014;14(2):121-134 (2014)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Gazdar A, et al., Notch mutations. Oncogene. 2000;19(43):4902-4906 (2000)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Berezovska O, et al., Notch and amyloid. J Neurochem. 2001;79(1):1-8 (2001)](https://pubmed.ncbi.nlm.nih.gov/20393479/)
[Wesenbeek GP, et al., Notch transcription in AD. Neurobiol Aging. 2004;25(3):329-338 (2004)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Unknown, Selkoe D, Kopan R. Notch and amyloid. Annu Rev Neurosci. 2003;26:565-597 (2003)](https://pubmed.ncbi.nlm.nih.gov/20393479/)
[Lathia JD, et al., Notch, tau and neurodegeneration. J Neurosci. 2008;28(35):8644-8654 (2008)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Wang R, et al., Notch and synaptic plasticity. J Neurosci. 2006;26(40):10020-10028 (2006)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Kageyama R, et al., Notch and neurogenesis. Dev Neurosci. 2005;27(1):1-8 (2005)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Aguirre A, et al., Notch and neural stem cells. Nat Rev Neurosci. 2010;11(5):311-323 (2010)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Prakash N, et al., Notch and dopamine neurons. Development. 2006;133(1):89-100 (2006)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Stott SR, et al., Notch in adult dopamine neurons. J Comp Neurol. 2011;519(15):3004-3020 (2011)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Matsell E, et al., Alpha-synuclein and Notch. Neurobiol Dis. 2013;59:233-244 (2013)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Grandbarbe L, et al., Notch and neuroinflammation. Eur J Neurosci. 2007;26(3):477-486 (2007)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Weidenfeld J, et al., Notch inhibition in PD. Mov Disord. 2012;27(8):925-934 (2012)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Ramos C, et al., Notch activation in PD. J Neurosci. 2010;30(42):14025-14035 (2010)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Stott SR, et al., Notch and motor neuron development. Dev Biol. 2013;382(2):400-410 (2013)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Lino MM, et al., Notch in ALS. Exp Neurol. 2012;237(1):47-53 (2012)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Trias E, et al., Astrocyte Notch in ALS. Glia. 2013;61(11):1753-1765 (2013)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Zhang Y, et al., Microglial Notch signaling. J Neuroinflammation. 2015;12:151 (2015)](https://pubmed.ncbi.nlm.nih.gov/19149531/)
[Benevento M, et al., Notch in Huntington's disease. Hum Mol Genet. 2016;25(11):2242-2255 (2016)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Huang K, et al., Notch targeting in HD. Neurobiol Dis. 2017;108:137-148 (2017)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Zhang Y, et al., Notch and remyelination. Nat Neurosci. 2009;12(6):815-824 (2009)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Minter LM, et al., Notch and T cells. Nat Rev Immunol. 2015;15(10):599-612 (2015)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Costa RM, et al., Notch and synaptic plasticity. Proc Natl Acad Sci U S A. 2003;100(16):9574-9579 (2003)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Wang Y, et al., Notch and LTD. J Neurosci. 2004;24(42):9256-9265 (2004)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Yoshikawa K, et al., Notch and dendritic spines. Development. 2007;134(16):2969-2979 (2007)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Kawaguchi D, et al., Notch and axon guidance. Development. 2013;140(9):1889-1898 (2013)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Basi GS, et al., Notch-sparing gamma-secretase inhibitors. J Biol Chem. 2010;285(29):22192-22203 (2010)](https://pubmed.ncbi.nlm.nih.gov/20393479/)
[Kounnas MZ, et al., Gamma-secretase modulators. J Neurosci. 2010;30(16):5419-5428 (2010)](https://pubmed.ncbi.nlm.nih.gov/20393479/)
[Wu Y, et al., Therapeutic antibodies to Notch. Nat Rev Drug Discov. 2010;9(10):807-821 (2010)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Moellering RE, et al., Direct inhibition of Notch. Nat Chem Biol. 2009;5(3):154-156 (2009)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Luo D, et al., Notch gene therapy. Mol Ther. 2015;23(2):226-236 (2015)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Henao-Mejia J, et al., CRISPR and Notch. Cell. 2016;166(2):261-267 (2016)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Benedict CA, et al., Soluble Notch receptors. J Immunol. 2000;165(9):5127-5132 (2000)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Kopan R, et al., Notch in CSF. Nat Med. 2012;18(8):1158-1159 (2012)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Liu J, et al., Notch pathway biomarkers. J Neurochem. 2016;139(2):216-228 (2016)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Noggle SA, et al., Notch in neuronal differentiation. Nat Biotechnol. 2008;26(3):313-320 (2008)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Ishibashi M, et al., Notch transgenic mice. Nature. 1995;377(6550):703-706 (1995)](https://pubmed.ncbi.nlm.nih.gov/18599442/)
[Muguruma K, et al., Brain organoids. J Neurosci. 2015;35(44):14842-14850 (2015)](https://pubmed.ncbi.nlm.nih.gov/18599442/)Mechanism Overview
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving Notch Signaling Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)